协和医学杂志

2020, v.11(02) 130-134

[打印本页] [关闭]
本期目录(Current Issue) | 过刊浏览(Past Issue) | 高级检索(Advanced Search)

贝利木单克隆抗体:治疗系统性红斑狼疮的新型靶向药物
Belimumab:A New Targeted Drug for Systemic Lupus Erythematosus

贺成美;张奉春;
HE Cheng-mei;ZHANG Feng-chun;Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College;

摘要(Abstract):

系统性红斑狼疮(systemic lupus erythematosus,SLE)是一种复杂的自身免疫性疾病,B细胞异常活化在发病中起重要作用。贝利木单克隆抗体是一种人源化单克隆抗体,能通过结合肿瘤坏死因子家族B细胞活化因子(B-cell-activating factor of the tumor necrosis factor family,BAFF),减少活化B细胞的数量。2011年美国食品药品监督管理局批准贝利木单克隆抗体上市,为SLE患者提供了新的用药选择。本文主要介绍贝利木单克隆抗体治疗机制及相关临床研究,并对其未来进行展望。
Systemic lupus erythematosus(SLE) is a complicated autoimmune disease characterized by aberrant B cell activation. Belimumab is a human monoclonal antibody, which can reduce active B cells through binding to the B-cell-activating factor of the tumor necrosis factor family(BAFF). In 2011, the US Food and Drugs Administration approved belimumab as a new drug option for SLE patients. This article mainly discusses the mechanism and relevant clinical trials of belimumab and looks forward to its future.

关键词(KeyWords): 系统性红斑狼疮;贝利木单克隆抗体;B淋巴细胞;肿瘤坏死因子家族B细胞活化因子
systemic lupus erythematosus;belimumab;B lymphocyte;B-cell-activating factor of the tumor necrosis factor family

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 贺成美;张奉春;
HE Cheng-mei;ZHANG Feng-chun;Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College;

Email:

DOI:

参考文献(References):

扩展功能
本文信息
服务与反馈
本文关键词相关文章
本文作者相关文章
中国知网
分享